COVID-19-related arrhythmias and the possible effects of ranolazine.
Action Potentials
Angina, Stable
/ complications
Anti-Arrhythmia Agents
/ therapeutic use
Arrhythmias, Cardiac
/ complications
COVID-19
/ complications
Cytokines
/ metabolism
Hemodynamics
Humans
Inflammation
Potassium Channels
/ metabolism
Ranolazine
/ therapeutic use
Sodium Channel Blockers
/ therapeutic use
COVID-19 Drug Treatment
Arrhythmias
COVID-19
Cytokine
Ranolazine
SARS-CoV-2
Journal
Medical hypotheses
ISSN: 1532-2777
Titre abrégé: Med Hypotheses
Pays: United States
ID NLM: 7505668
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
05
01
2021
revised:
03
02
2021
accepted:
12
02
2021
pubmed:
27
2
2021
medline:
16
4
2021
entrez:
26
2
2021
Statut:
ppublish
Résumé
The COVID-19 pandemic has become a burden to the global healthcare community. Despite the severity of the complications associated with COVID-19, no antiviral agent is yet available for the treatment of this disease. Several studies have reported arrhythmias as one of the numerous manifestations associated with COVID-19 infection. Clinicians use different therapeutic agents in the management of COVID-19 patients with arrhythmias, apart from ranolazine; however, some of these drugs are administered with caution because of their significant side effects. In this study, we reviewed the potential antiarrhythmic effects of ranolazine in the management of cardiac arrhythmias associated with COVID-19. Ranolazine is a second-line drug approved for the treatment of chronic stable angina pectoris. Previous studies have shown that ranolazine produces its beneficial cardiac effects without any significant impact on the body's hemodynamics; hence, blood pressure is not altered. Due to its reduced side effects, ranolazine may be more effective than other drugs in producing the desired relief from COVID-19 related arrhythmias, since it produces its antiarrhythmic effect by modulating sodium, potassium and calcium channels, and suppressing cytokine expression.
Identifiants
pubmed: 33636586
pii: S0306-9877(21)00063-3
doi: 10.1016/j.mehy.2021.110545
pmc: PMC7890340
pii:
doi:
Substances chimiques
Anti-Arrhythmia Agents
0
Cytokines
0
Potassium Channels
0
Sodium Channel Blockers
0
Ranolazine
A6IEZ5M406
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
110545Informations de copyright
Copyright © 2021 Elsevier Ltd. All rights reserved.
Références
Circulation. 2006 May 23;113(20):2462-72
pubmed: 16717165
Curr Drug Targets Inflamm Allergy. 2004 Dec;3(4):361-75
pubmed: 15584886
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
Nat Commun. 2016 Oct 04;7:12966
pubmed: 27701382
Ann Noninvasive Electrocardiol. 2014 Jul;19(4):345-50
pubmed: 24533675
Circ Res. 2000 Sep 1;87(5):E1-9
pubmed: 10969042
Cardiovasc Hematol Agents Med Chem. 2015;13(1):31-9
pubmed: 26245658
Expert Rev Cardiovasc Ther. 2011 Jul;9(7):815-27
pubmed: 21809962
JACC Clin Electrophysiol. 2020 Sep;6(9):1189-1190
pubmed: 32972558
Indian Pacing Electrophysiol J. 2011 May 01;11(3):84-8
pubmed: 21556158
J Heart Lung Transplant. 2020 May;39(5):405-407
pubmed: 32362390
PLoS One. 2016 Mar 07;11(3):e0150619
pubmed: 26950436
Circ Arrhythm Electrophysiol. 2015 Oct;8(5):1048-56
pubmed: 26226999
Front Physiol. 2019 Jan 07;9:1866
pubmed: 30666212
FEBS Lett. 2002 Dec 4;532(1-2):107-10
pubmed: 12459472
Heart Rhythm. 2011 Aug;8(8):1281-90
pubmed: 21421082
Europace. 2013 Mar;15(3):429-36
pubmed: 23258816
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
JAMA Cardiol. 2020 Jul 1;5(7):811-818
pubmed: 32219356
J Mol Cell Cardiol. 2007 Dec;43(6):710-6
pubmed: 17961593
JAMA. 2020 Apr 28;323(16):1612-1614
pubmed: 32191259
J Physiol. 2017 Jun 15;595(12):3799-3813
pubmed: 28177123
Cardiovasc Toxicol. 2017 Oct;17(4):434-440
pubmed: 28213753
Nat Rev Immunol. 2020 May;20(5):271-272
pubmed: 32296135
Circulation. 2007 Sep 25;116(13):1449-57
pubmed: 17785620
Vasc Health Risk Manag. 2014 Jun 24;10:353-62
pubmed: 25028555
Circulation. 2004 Aug 24;110(8):904-10
pubmed: 15302796
J Biol Chem. 2004 Apr 2;279(14):13289-92
pubmed: 14973143
J Pathol. 2004 Jun;203(2):631-7
pubmed: 15141377
Am J Cardiol. 2011 Sep 1;108(5):673-6
pubmed: 21726841
Clin Pharmacokinet. 2006;45(5):469-91
pubmed: 16640453
Heart Rhythm. 2008 Jul;5(7):1019-26
pubmed: 18598958
JAMA Cardiol. 2020 Jul 1;5(7):802-810
pubmed: 32211816
Nat Commun. 2016 Nov 24;7:13344
pubmed: 27882934
J Gen Virol. 2008 Nov;89(Pt 11):2741-2745
pubmed: 18931070
Circulation. 2007 Oct 9;116(15):1647-52
pubmed: 17804441
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Ann Noninvasive Electrocardiol. 2020 Nov;25(6):e12805
pubmed: 32951285
JACC Basic Transl Sci. 2020 Apr 10;5(5):518-536
pubmed: 32292848
Heart Rhythm. 2015 Oct;12(10):2186-94
pubmed: 26025323
Pacing Clin Electrophysiol. 2012 Mar;35(3):302-7
pubmed: 22229482
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508